MLN8237 for a Subject With Adenocarcinoma of the Prostate
NCT03005262 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2018-04-04
Summary
To allow a patient continued access to MLN8237
Conditions
Interventions
- DRUG
-
MLN8237
Sponsors & Collaborators
-
The University of Texas Health Science Center at San Antonio
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
NCT05204927 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236 ·Status: RECRUITING ·Phase: PHASE1
-
Lenalidomide and Paclitaxel in Prostate Cancer
NCT00933426 ·Status: TERMINATED ·Phase: PHASE1
-
Development of a Novel Signature Integrating Clinical, Imaging And Epigenetic Information to Tailor Pelvic Nodal Treatment in Prostate Cancer
NCT06807398 ·Status: COMPLETED
-
The Safety and Dosimetry Study of 177Lu-LNC1003 Injection
NCT06237491 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
NCT02268175 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
NCT00502164 ·Status: COMPLETED ·Phase: PHASE1
-
Health-Related Quality of Life in Gay Men With Localized Prostate Cancer
NCT00828633 ·Status: COMPLETED
-
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
NCT06520345 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
NCT01799278 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
NCT04633252 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer
NCT00326586 ·Status: COMPLETED ·Phase: PHASE1
-
[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
NCT06229366 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
NCT03796767 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Open-label Extension Study of PSMA ADC 2301 in mCRPC
NCT02020135 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer
NCT06809426 ·Status: COMPLETED ·Phase: NA
-
MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer
NCT00070837 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Trial of Targeted Alpha Therapy Using [At-211]PSMA-5 for Prostate Cancer
NCT06441994 ·Status: RECRUITING ·Phase: PHASE1
-
An Alternative to A Fixed Schedule In Management Of Prostate Cancer
NCT01056562 ·Status: COMPLETED
-
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
NCT04109729 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer
NCT02008058 ·Status: COMPLETED
-
Study Using CP-461 to Treat Advanced Prostate Cancer
NCT00036075 ·Status: COMPLETED ·Phase: PHASE2
-
Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201
NCT02887976 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
NCT00052000 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
NCT00521781 ·Status: TERMINATED ·Phase: PHASE2